- Trials with a EudraCT protocol (336)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
336 result(s) found for: Drug culture.
Displaying page 1 of 17.
EudraCT Number: 2012-000780-24 | Sponsor Protocol Number: 9463-CL-2303 | Start Date*: 2012-07-24 |
Sponsor Name:Astellas Pharma Global Development, Inc. | ||
Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | ||
Medical condition: Neonatal Candidiasis | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GR (Completed) HU (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001916-41 | Sponsor Protocol Number: C11-11 | Start Date*: 2014-11-24 |
Sponsor Name:Inserm | ||
Full Title: Fluconazole versus Micafungin in neonates with suspected or culture-proven Candidiasis: a randomized pharmacokinetic and safety study | ||
Medical condition: Neonates with suspected or culture-proven candidiasis | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Prematurely Ended) NL (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005278-11 | Sponsor Protocol Number: A8851022 | Start Date*: 2009-03-06 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005277-35 | Sponsor Protocol Number: A8851021 | Start Date*: 2009-02-26 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) SK (Prematurely Ended) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001699-43 | Sponsor Protocol Number: BPR-CS-009 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ... | |||||||||||||
Medical condition: Complicated staphylococcus aureus bacteremia (cSAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002955-33 | Sponsor Protocol Number: 027SC10363 | Start Date*: 2012-02-16 |
Sponsor Name:Aziende Chimiche Riunite Angelini Francesco S.p.A | ||
Full Title: Clinical and microbiological assessment of prulifloxacin in patients with Acute Bacterial Rhinosinusitis (ABRS) | ||
Medical condition: Male or female adults with ABRS, defined as the presence of 2 (including at least one between nasal blockage/congestion/ obstruction or nasal discharge) or more of the following signs and symptoms:... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003079-16 | Sponsor Protocol Number: INS-416 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen ... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) DE (Ongoing) AT (Trial now transitioned) HU (Completed) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000653-23 | Sponsor Protocol Number: TMC207-TiDP13-C210 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004804-38 | Sponsor Protocol Number: 073-202 | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:ViroDefense Inc | |||||||||||||
Full Title: A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult V... | |||||||||||||
Medical condition: Poliomyelitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001626-22 | Sponsor Protocol Number: RML-TB | Start Date*: 2022-03-28 |
Sponsor Name:Vall d'Hebron Institute of Research | ||
Full Title: A Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezoli... | ||
Medical condition: Smear-positive rifampicin-sensitive pulmonary Tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005010-31 | Sponsor Protocol Number: INS-212 | Start Date*: 2015-07-03 | |||||||||||
Sponsor Name:Insmed Inc. | |||||||||||||
Full Title: A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium comple... | |||||||||||||
Medical condition: Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) IT (Completed) NL (Completed) ES (Completed) PL (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001269-18 | Sponsor Protocol Number: VMT-VT-1161-CL-011 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Mycovia Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis | |||||||||||||
Medical condition: Recurrent Vulvovaginal Candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004084-10 | Sponsor Protocol Number: T001018N | Start Date*: 2022-05-16 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Flemisch Fund for Scientific Research - Fonds voor Wetenschappelijk Onderzoek | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment; a pragmatic randomised controlled trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Rifampicin resistant (RR-TB) and drug resistant (DR-TB) tuberculosis | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012848-16 | Sponsor Protocol Number: A1501085 | Start Date*: 2010-04-28 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA | |||||||||||||||||||||||
Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH... | |||||||||||||||||||||||
Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016590-15 | Sponsor Protocol Number: CTBM100C2304 | Start Date*: 2009-12-29 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infection... | |||||||||||||||||||||||
Medical condition: Lung colonisation with Pseudomonas aeruginosa in cystic fibrosis patients | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) GR (Completed) DE (Completed) IT (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005738-13 | Sponsor Protocol Number: TPLBIS20 | Start Date*: 2021-02-16 |
Sponsor Name:Region Skåne | ||
Full Title: Pivmecillinam with Amoxicillin/clavulanic acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales. | ||
Medical condition: Urinary tract infection and/or bacteremia caused by extended spectrum beta-lactamases-producing Enterobacterales | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000910-12 | Sponsor Protocol Number: HT011 | Start Date*: 2020-07-01 | |||||||||||
Sponsor Name:Helperby Therapeutics Ireland Limited | |||||||||||||
Full Title: A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colis... | |||||||||||||
Medical condition: complicated urinary tract infection (cUTI). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004040-36 | Sponsor Protocol Number: CE01-302 | Start Date*: 2014-10-10 |
Sponsor Name:Cempra Pharmaceuticals, Inc. | ||
Full Title: A Study to Evaluate the Efficacy and Safety of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea (SOLITAIRE-U). | ||
Medical condition: gonorrhoea | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2005-000060-16 | Sponsor Protocol Number: AMIK-04-02 | Start Date*: 2005-05-06 |
Sponsor Name:Aerogen, Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Patients With Ventilator-Associated Pn... | ||
Medical condition: Ventilator associated pneumonia (VAP) caused by gram negative organisms. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002545-42 | Sponsor Protocol Number: INS-415 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous M... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) HU (Completed) AT (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
